The stock of Unicycive Therapeutics Inc (UNCY) has gone up by 9.33% for the week, with a 61.62% rise in the past month and a 64.76% rise in the past quarter. The volatility ratio for the week is 9.83%, and the volatility levels for the past 30 days are 9.55% for UNCY. The simple moving average for the past 20 days is 27.97% for UNCY’s stock, with a -26.58% simple moving average for the past 200 days.
Is It Worth Investing in Unicycive Therapeutics Inc (NASDAQ: UNCY) Right Now?
Additionally, the 36-month beta value for UNCY is 2.23. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for UNCY is 84.53M and currently, short sellers hold a 1.24% ratio of that float. The average trading volume of UNCY on November 07, 2024 was 2.23M shares.
UNCY) stock’s latest price update
Unicycive Therapeutics Inc (NASDAQ: UNCY)’s stock price has plunge by 16.51relation to previous closing price of 0.50. Nevertheless, the company has seen a 9.33% surge in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-28 that – Late-Breaker Poster Presentation Highlights Favorable Safety & Tolerability of OLC – – Two Publications Recently Issued Featuring OLC and UNI-494 – LOS ALTOS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that multiple presentations were delivered at the American Society of Nephrology (ASN) Kidney Week 2024 that highlighted the extensive development progress for both oxylanthanum carbonate (OLC) and UNI-494.
Analysts’ Opinion of UNCY
Many brokerage firms have already submitted their reports for UNCY stocks, with Piper Sandler repeating the rating for UNCY by listing it as a “Overweight.” The predicted price for UNCY in the upcoming period, according to Piper Sandler is $9 based on the research report published on April 04, 2024 of the current year 2024.
UNCY Trading at 41.75% from the 50-Day Moving Average
After a stumble in the market that brought UNCY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.83% of loss for the given period.
Volatility was left at 9.55%, however, over the last 30 days, the volatility rate increased by 9.83%, as shares surge +60.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +72.32% upper at present.
During the last 5 trading sessions, UNCY rose by +7.42%, which changed the moving average for the period of 200-days by -40.14% in comparison to the 20-day moving average, which settled at $0.4561. In addition, Unicycive Therapeutics Inc saw -32.59% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for UNCY
Current profitability levels for the company are sitting at:
- 106.48 for the present operating margin
- 2.64 for the gross margin
The net margin for Unicycive Therapeutics Inc stands at 107.88. The total capital return value is set at -0.91. Equity return is now at value -700.45, with -86.30 for asset returns.
Based on Unicycive Therapeutics Inc (UNCY), the company’s capital structure generated 1.47 points at debt to capital in total, while cash flow to debt ratio is standing at -0.46. The debt to equity ratio resting at -3.14. The interest coverage ratio of the stock is -779.89.
Currently, EBITDA for the company is -20.49 million with net debt to EBITDA at -0.18. When we switch over and look at the enterprise to sales, we see a ratio of -215.98. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.37.
Conclusion
In conclusion, Unicycive Therapeutics Inc (UNCY) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
